In bladder cancer, high tumor mutational burden and (programmed death-1) (PD-L1) expression have been correlated with response to atezolizumab and nivolumab, although not all patients with high PD-L1 respond, highlighting the complexity of predictive modeling. Here, CD274 is linked to urinary bladder cancer.